In just 10 months, she reached her weight loss goal with the help of the injectable semaglutide medication, Tirzepatide. 'I probably have not weighed this much since I was prepubescent,' Bonnie ...

Like semaglutide, this is one of the diabetes drugs for weight loss that’s injected once weekly. Tirzepatide is the active ingredient in the brand-name drugs Mounjaro® and Zepbound®.

Traditionally, treatments that have been used for MASH have included lifestyle modification and off-label use of therapies such as semaglutide or tirzepatide (marketed as Mounjaro for diabetes and ...

BIGBANG’s G-Dragon is back—and topping music charts across the globe! On October 31 at 6 p.m. KST, G-Dragon made his long-awaited solo return with his new pre-release single “POWER.” ...

A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Hsieh’s team said that investors are now rallying around the potential of GLP-1s like semaglutide in MASH, citing recent promising results from Eli Lilly’s tirzepatide and Boehringer Ingelheim ...

Part 1 of the trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.

You’ve probably heard of them under brand names like Ozempi c® and Wegovy® (semaglutide) or Monjouro and Zepbound (tirzepatide). But what’s the deal with compounded GLP-1s? Compounded ...

The study funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy, involved 407 participants taking either the active ingredient semaglutide or a placebo for 68 weeks. Roughly 82 percent of ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, a similar situation is playing out for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end ...